Open in Screener

PTCT

PTC Therapeutics Inc

Oct 07 • 02:54PM ET

63.68

-1.12 -1.73 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: VTI IWM VB XBI VBK VXF IWO CALF IBB SCHA

Index	RUT	P/E	9.13	EPS (ttm)	6.97	Insider Own	4.29%	Shs Outstand	79.38M	Perf Week	3.76%
Market Cap	5.06B	Forward P/E	-	EPS next Y	-3.01	Insider Trans	-3.90%	Shs Float	76.03M	Perf Month	11.82%
Enterprise Value	3.46B	PEG	0.22	EPS next Q	-0.99	Inst Own	100.01%	Short Float	9.59%	Perf Quarter	30.65%
Income	629.17M	P/S	2.87	EPS this Y	257.80%	Inst Trans	1.90%	Short Ratio	5.71	Perf Half Y	48.72%
Sales	1.76B	P/B	-	EPS next Y	-140.38%	ROA	27.65%	Short Interest	7.29M	Perf YTD	41.07%
Book/sh	-2.60	P/C	2.54	EPS next 5Y	42.39%	ROE	-	52W High	67.40 -5.52%	Perf Year	80.04%
Cash/sh	25.04	P/FCF	7.25	EPS past 3/5Y	14.01% -2.04%	ROIC	382.39%	52W Low	34.57 84.21%	Perf 3Y	26.85%
Dividend Est.	-	EV/EBITDA	3.86	Sales past 3/5Y	14.42% 21.32%	Gross Margin	96.28%	Volatility	3.47% 3.62%	Perf 5Y	36.21%
Dividend TTM	-	EV/Sales	1.96	EPS Y/Y TTM	227.02%	Oper. Margin	49.11%	ATR (14)	2.27	Perf 10Y	135.76%
Dividend Ex-Date	-	Quick Ratio	3.57	Sales Y/Y TTM	96.00%	Profit Margin	35.65%	RSI (14)	63.84	Recom	1.94
Dividend Gr. 3/5Y	- -	Current Ratio	3.62	EPS Q/Q	35.80%	SMA20	4.25%	Beta	0.59	Target Price	65.80
Payout	-	Debt/Eq	-	Sales Q/Q	-4.19%	SMA50	16.00%	Rel Volume	0.55	Prev Close	64.80
Employees	939	LT Debt/Eq	-	Earnings	Aug 07 AMC	SMA200	27.37%	Avg Volume	1.28M	Price	63.68
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.74% 3.82%	Trades		Volume	592,223	Change	-1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35

Show Previous Ratings

Oct-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-25 11:15AM	PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU (Insider Monkey)
Sep-05-25 08:35AM	Here's Why Shares in PTC Therapeutics Soared This Week (Motley Fool)
Sep-03-25 02:03PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily) +5.95%
Aug-29-25 04:52AM	PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich's Ataxia (Insider Monkey)
08:00AM	Loading…
Aug-21-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
10:35AM	PTC Therapeutics CRL expected, focus moves to Sephience, says RBC Capital (TipRanks)
Aug-19-25 08:00AM	PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA (PR Newswire)
07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-07-25 06:00PM	PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.89%
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
10:01AM	Loading…
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
08:00AM	Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE (sepiapterin) (PR Newswire)
Jul-28-25 04:19PM	PTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire) +11.16%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-21-25 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results (PR Newswire)
Jul-09-25 09:36AM	Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	Loading…
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
Dec-04-24 07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily) +18.66%
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)
12:40PM	PTC Therapeutics Stock Soars on Novartis Licensing Agreement (Investopedia)
11:29AM	Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% (GuruFocus.com)
07:00AM	PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program (PR Newswire)
05:56AM	Novartis wagers billions of dollars on PTC Huntingtons drug (BioPharma Dive)
Nov-28-24 07:11AM	PTC Therapeutics to sell Priority Review Voucher for $150M (TipRanks)
Nov-27-24 10:12AM	PTC Therapeutics ALS drug fails to meet endpoints as trials shut down (Clinical Trials Arena)
07:51AM	PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs (Benzinga)
07:00AM	PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million (PR Newswire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 04:30PM	PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients (PR Newswire) +7.02%
Nov-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-14-24 01:46PM	FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain (Benzinga)
10:00AM	FDA grants accelerated approval for PTCs AADC deficiency gene therapy (Pharmaceutical Technology)
06:28AM	PTC wins US approval of gene therapy for fatal enzyme disorder (BioPharma Dive)
Nov-13-24 06:02PM	PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy (PR Newswire)
Nov-08-24 10:05AM	PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 06:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-06-24 09:15AM	Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks) +5.65%
07:11AM	PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boulding Mark Elliott	Officer	Oct 06 '25	Proposed Sale	65.07	2,266	147,453		Oct 06 05:16 PM
Boulding Mark Elliott	Officer	Oct 03 '25	Proposed Sale	65.82	22,655	1,491,105		Oct 03 04:40 PM
Reeve Emma	Director	Oct 03 '25	Proposed Sale	65.96	25,562	1,685,979		Oct 03 04:38 PM
Almstead Neil Gregory	Officer	Oct 03 '25	Proposed Sale	66.05	55,000	3,632,947		Oct 03 04:33 PM
Jacobson Allan Steven	Director	Oct 03 '25	Proposed Sale	65.00	12,000	780,000		Oct 03 12:04 PM
Reeve Emma	Director	Sep 11 '25	Option Exercise	26.30	10,837	285,048	20,332	Sep 16 05:00 PM
Reeve Emma	Director	Sep 11 '25	Sale	59.50	15,705	934,448	10,332	Sep 16 05:00 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Sep 12 '25	Option Exercise	38.10	24,585	936,688	126,562	Sep 15 05:00 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Sep 11 '25	Option Exercise	38.10	22,664	863,498	121,739	Sep 15 05:00 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Sep 12 '25	Sale	61.34	24,585	1,508,083	103,901	Sep 15 05:00 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Sep 11 '25	Sale	61.00	22,664	1,382,504	103,901	Sep 15 05:00 PM
Boulding Mark Elliott	Officer	Sep 12 '25	Proposed Sale	61.34	24,585	1,508,094		Sep 12 04:35 PM
SOUTHWELL DAVID P	Director	Sep 09 '25	Option Exercise	30.86	12,000	370,320	28,850	Sep 11 04:30 PM
SOUTHWELL DAVID P	Director	Sep 09 '25	Sale	58.34	12,000	700,080	16,850	Sep 11 04:30 PM
Boulding Mark Elliott	Officer	Sep 11 '25	Proposed Sale	61.00	22,664	1,382,537		Sep 11 04:29 PM
Reeve Emma	Director	Sep 11 '25	Proposed Sale	59.50	15,705	934,448		Sep 11 11:18 AM
Pauwels Eric	CHIEF BUSINESS OFFICER	Sep 08 '25	Option Exercise	22.74	39,850	906,227	89,610	Sep 09 05:00 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Sep 08 '25	Sale	56.92	39,850	2,268,374	72,912	Sep 09 05:00 PM
SOUTHWELL DAVID P	Director	Sep 09 '25	Proposed Sale	58.34	12,000	700,129		Sep 09 03:28 PM
Pauwels Eric	Officer	Sep 08 '25	Proposed Sale	56.92	39,850	2,268,374		Sep 08 04:23 PM
Jacobson Allan Steven	Director	Aug 28 '25	Sale	50.15	1,667	83,600	17,451	Sep 02 05:00 PM
Jacobson Allan Steven	Director	Aug 28 '25	Proposed Sale	50.15	1,667	83,602		Aug 28 10:08 AM
Boulding Mark Elliott	EXEC. VP AND CLO	Aug 15 '25	Option Exercise	25.69	2,813	72,266	106,714	Aug 19 04:30 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Aug 15 '25	Sale	48.58	2,813	136,656	103,901	Aug 19 04:30 PM
Boulding Mark Elliott	Officer	Aug 15 '25	Proposed Sale	48.58	2,813	136,646		Aug 15 04:11 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Aug 05 '25	Sale	51.74	10,739	555,636	337,767	Aug 05 08:30 PM
Klein Matthew B.	Officer	Aug 05 '25	Proposed Sale	51.74	10,739	555,663		Aug 05 03:16 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jul 15 '25	Sale	49.46	2,516	124,441	71,920	Jul 17 05:20 PM
Gravier Pierre	Officer	Jul 15 '25	Proposed Sale	49.46	2,516	124,435		Jul 15 03:25 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 15 '25	Option Exercise	25.69	1,929	49,556	105,830	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 16 '25	Option Exercise	25.69	883	22,684	104,784	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 15 '25	Sale	46.18	1,929	89,081	103,901	May 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	May 16 '25	Sale	46.02	883	40,636	103,901	May 19 05:20 PM
Boulding Mark Elliott	Officer	May 16 '25	Proposed Sale	46.02	883	40,640		May 16 04:25 PM
Boulding Mark Elliott	Officer	May 15 '25	Proposed Sale	46.18	1,929	89,076		May 15 04:23 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 22 '25	Sale	48.74	2,804	136,656	273,234	Apr 24 05:20 PM
Klein Matthew B.	Officer	Apr 22 '25	Proposed Sale	48.74	2,804	136,656		Apr 22 03:14 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Apr 02 '25	Sale	46.95	897	42,114	75,997	Apr 04 05:20 PM
Golden Lee Scott	Officer	Apr 02 '25	Proposed Sale	46.95	897	42,117		Apr 02 03:24 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 17 '25	Sale	56.80	6,762	384,067	72,640	Mar 18 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Mar 14 '25	Sale	55.19	4,458	246,037	79,402	Mar 18 05:20 PM
Okey Stephanie	Director	Mar 13 '25	Sale	54.00	5,000	270,000	8,867	Mar 17 05:20 PM
Pauwels Eric	Officer	Mar 17 '25	Proposed Sale	56.80	6,762	384,064		Mar 17 04:48 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Option Exercise	33.02	15,521	512,503	117,027	Mar 14 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 12 '25	Sale	53.30	15,521	827,233	103,901	Mar 14 05:20 PM
Pauwels Eric	Officer	Mar 14 '25	Proposed Sale	55.19	4,458	246,024		Mar 14 04:24 PM
Okey Stephanie	Director	Mar 13 '25	Proposed Sale	54.00	5,000	270,000		Mar 13 10:23 AM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Option Exercise	31.81	68,039	2,164,193	149,293	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Option Exercise	33.02	7,381	243,721	109,563	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 10 '25	Sale	53.09	68,039	3,611,982	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Mar 11 '25	Sale	53.02	7,381	391,323	103,901	Mar 12 05:20 PM
Boulding Mark Elliott	Officer	Mar 12 '25	Proposed Sale	53.30	15,521	827,199		Mar 12 04:33 PM
Boulding Mark Elliott	Officer	Mar 11 '25	Proposed Sale	53.02	7,381	391,321		Mar 11 04:21 PM
Boulding Mark Elliott	Officer	Mar 10 '25	Proposed Sale	53.09	68,039	3,612,075		Mar 10 04:28 PM
Jacobson Allan Steven	Director	Mar 04 '25	Sale	51.52	1,230	63,370	19,118	Mar 06 05:20 PM
Jacobson Allan Steven	Director	Mar 04 '25	Proposed Sale	51.52	1,230	63,365		Mar 04 12:35 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 19 '25	Sale	50.10	879	44,034	63,442	Feb 21 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Feb 20 '25	Sale	50.12	878	44,009	62,564	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 19 '25	Sale	50.10	1,168	58,512	75,603	Feb 21 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Feb 20 '25	Sale	50.12	1,167	58,495	74,436	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	1,567	78,544	83,860	Feb 21 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	1,378	69,032	85,427	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 20 '25	Sale	50.12	3,895	195,233	276,038	Feb 21 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	50.10	3,897	195,224	279,933	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 20 '25	Sale	50.12	962	48,219	76,894	Feb 21 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Feb 19 '25	Sale	50.10	795	39,826	77,856	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 20 '25	Sale	50.12	1,614	80,900	103,901	Feb 21 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Feb 19 '25	Sale	50.10	1,333	66,778	105,515	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	1,578	79,096	100,353	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	1,300	65,125	101,931	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 20 '25	Sale	50.12	34	1,704	5,907	Feb 21 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Feb 19 '25	Sale	50.10	34	1,703	5,941	Feb 21 05:20 PM
Almstead Neil Gregory	Officer	Feb 20 '25	Proposed Sale	50.12	1,578	79,096		Feb 20 04:47 PM
Almstead Neil Gregory	Member of immediate family of	Feb 20 '25	Proposed Sale	50.12	34	1,704		Feb 20 04:33 PM
Boulding Mark Elliott	Officer	Feb 20 '25	Proposed Sale	50.12	1,614	80,900		Feb 20 04:32 PM
Utter Christine Marie	Officer	Feb 20 '25	Proposed Sale	50.12	878	44,009		Feb 20 04:21 PM
Klein Matthew B.	Officer	Feb 20 '25	Proposed Sale	50.12	3,895	195,233		Feb 20 04:20 PM
Golden Lee Scott	Officer	Feb 20 '25	Proposed Sale	50.12	962	48,219		Feb 20 04:18 PM
Gravier Pierre	Officer	Feb 20 '25	Proposed Sale	50.12	1,167	58,495		Feb 20 04:17 PM
Pauwels Eric	Officer	Feb 20 '25	Proposed Sale	50.12	1,567	78,544		Feb 20 04:10 PM
Almstead Neil Gregory	Member of immediate family of	Feb 19 '25	Proposed Sale	50.10	34	1,703		Feb 19 04:36 PM
Almstead Neil Gregory	Officer	Feb 19 '25	Proposed Sale	50.10	1,300	65,125		Feb 19 04:34 PM
Utter Christine Marie	Officer	Feb 19 '25	Proposed Sale	50.10	879	44,035		Feb 19 04:27 PM
Gravier Pierre	Officer	Feb 19 '25	Proposed Sale	50.10	1,168	58,513		Feb 19 04:25 PM
Boulding Mark Elliott	Officer	Feb 19 '25	Proposed Sale	50.10	1,333	66,778		Feb 19 04:18 PM
Klein Matthew B.	Officer	Feb 19 '25	Proposed Sale	50.10	3,897	195,226		Feb 19 04:18 PM
Golden Lee Scott	Officer	Feb 19 '25	Proposed Sale	50.10	795	39,827		Feb 19 04:13 PM
Pauwels Eric	Officer	Feb 19 '25	Proposed Sale	50.10	1,378	69,033		Feb 19 04:11 PM
Bell William F. Jr.	Former Director	Feb 03 '25	Proposed Sale	50.00	10,556	527,800		Feb 03 02:14 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '25	Sale	44.50	1,662	73,959	64,321	Jan 10 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '25	Sale	45.34	1,291	58,534	65,983	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,136	95,052	86,805	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	1,599	72,499	88,941	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,402	106,889	283,830	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	2,142	97,118	286,232	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '25	Sale	44.50	1,198	53,311	78,651	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '25	Sale	45.34	810	36,725	79,849	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '25	Sale	44.50	1,998	88,911	106,848	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '25	Sale	45.34	1,543	69,960	108,846	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	1,552	69,064	103,231	Jan 10 05:20 PM

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

Oct 07 • 02:54PM ET

3.16

-0.02 -0.72 %

Healthcare • Biotechnology • USA • NASD

RCKT Rocket Pharmaceuticals Inc daily Stock Chart

Peers: SRPT CRSP NTLA QURE BLUE EDIT ALLO SGMO ADVM VYGR

| Held by: VTI IWM VXF IWN IBB SCHA VTWO FESM VHT PRFZ

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	8.55%	Shs Outstand	107.88M	Perf Week	-3.15%
Market Cap	340.67M	Forward P/E	-	EPS next Y	-1.19	Insider Trans	-0.08%	Shs Float	98.68M	Perf Month	-3.15%
Enterprise Value	94.38M	PEG	-	EPS next Q	-0.49	Inst Own	85.78%	Short Float	15.09%	Perf Quarter	-1.34%
Income	-257.30M	P/S	-	EPS this Y	24.65%	Inst Trans	-13.51%	Short Ratio	4.07	Perf Half Y	-39.17%
Sales	0.00M	P/B	0.96	EPS next Y	42.09%	ROA	-59.33%	Short Interest	14.89M	Perf YTD	-74.88%
Book/sh	3.28	P/C	1.25	EPS next 5Y	20.15%	ROE	-69.65%	52W High	18.89 -83.29%	Perf Year	-80.34%
Cash/sh	2.52	P/FCF	-	EPS past 3/5Y	-0.69% -11.60%	ROIC	-68.34%	52W Low	2.19 44.16%	Perf 3Y	-80.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.02% 5.40%	Perf 5Y	-86.19%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	10.36%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	-91.22%
Dividend Ex-Date	-	Quick Ratio	6.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.79	Recom	2.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.39	EPS Q/Q	16.44%	SMA20	-1.04%	Beta	0.68	Target Price	7.69
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	-1.06%	Rel Volume	0.53	Prev Close	3.18
Employees	299	LT Debt/Eq	0.06	Earnings	Aug 07 AMC	SMA200	-48.68%	Avg Volume	3.66M	Price	3.16
IPO	Feb 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.16% -	Trades		Volume	1,625,957	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy	$10
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral	$4
May-30-25	Downgrade	Evercore ISI	Outperform → In-line	$5
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$8
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold	$2.50
May-28-25	Downgrade	Goldman	Neutral → Sell	$2
May-27-25	Downgrade	TD Cowen	Buy → Hold
May-27-25	Downgrade	Needham	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Dec-30-24	Initiated	Wedbush	Outperform	$32
Dec-18-24	Initiated	Jefferies	Buy	$29
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22

Show Previous Ratings

Oct-03-25 11:33AM	Rocket ditches blood disorder gene therapy in ongoing pipeline pivot (Pharmaceutical Technology)
Aug-28-25 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
07:10AM	Rocket to relaunch rare disease trial after FDA approval (Clinical Trials Arena)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com) +28.87%
10:30AM	Loading…
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease (Business Wire)
06:46AM	Rocket can resume gene therapy trial after FDA lifts hold (BioPharma Dive)
Aug-19-25 12:09AM	Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating (Insider Monkey)
Aug-17-25 11:41PM	Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform (Insider Monkey)
Aug-07-25 04:07PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.44%
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Aug-06-25 04:24PM	Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 (Newsfile)
Aug-05-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-30-25 04:37PM	Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025 (Newsfile)
01:14PM	Loading…
01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com)
Jul-29-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-24-25 07:00AM	Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -8.98%
Jul-17-25 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy (Business Wire) +16.78%
Jul-15-25 08:58AM	Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701 (Insider Monkey) -7.87%
Jul-10-25 09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +5.71%
09:00AM	Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
07:25AM	Rocket Pharmaceuticals receives FDA clearance of RP-A701 (TipRanks)
Jun-30-25 07:00AM	Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy (Business Wire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:00AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
06:00PM	Loading…
May-28-25 06:00PM	Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow (Insider Monkey) +6.44% +5.65%
01:20PM	William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback (Insider Monkey)
11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
May-27-25 08:01PM	Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death (Insider Monkey) -62.84%
11:50AM	Top Stock Movers Now: Tesla, AutoZone, Newmont, and More (Investopedia)
11:35AM	Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies (Investopedia)
10:37AM	CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers (Yahoo Finance Video)
07:00AM	Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease (Business Wire)
May-15-25 03:15PM	Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire) +11.07%
May-13-25 08:54AM	Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey) -5.50%
May-09-25 04:30PM	Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-08-25 04:01PM	Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire) +5.07%
Apr-16-25 11:59AM	Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz (TipRanks) -5.82%
Apr-10-25 11:16AM	Rocket Pharma Out Of Orbit, But Ready For Relaunch (Seeking Alpha) -8.52%
Apr-09-25 10:55AM	Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.73%
Apr-03-25 07:00AM	Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -11.75%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -12.89%
Mar-26-25 10:40AM	Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? (InsiderMonkey) -5.88%
Feb-27-25 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jan-02-25 04:00PM	Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 08:05AM	Wedbush starts Rocket Pharmaceuticals with Outperform into inflection year (TipRanks)
Dec-18-24 02:16PM	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' (Investopedia)
Dec-11-24 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)
Nov-08-24 07:00AM	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-07-24 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily) +9.21%
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bjork Elisabeth	Director	Aug 27 '25	Buy	3.41	10,000	34,100	40,000	Aug 27 08:54 PM
Militello John	See Remarks	Aug 18 '25	Sale	3.06	699	2,142	56,285	Aug 20 05:00 PM
Militello John	See Remarks	Aug 19 '25	Sale	3.00	361	1,082	55,924	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 18 '25	Sale	3.06	1,680	5,149	222,414	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 19 '25	Sale	3.00	805	2,412	221,609	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 18 '25	Sale	3.06	1,004	3,077	136,050	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 19 '25	Sale	3.00	588	1,762	135,462	Aug 20 05:00 PM
Wilson Martin	Officer	Aug 19 '25	Proposed Sale	3.00	588	1,762		Aug 19 03:33 PM
Schwartz Jonathan David	Officer	Aug 19 '25	Proposed Sale	3.00	805	2,412		Aug 19 03:28 PM
Militello John	Officer	Aug 19 '25	Proposed Sale	3.00	361	1,082		Aug 19 03:28 PM
Schwartz Jonathan David	See Remarks	Aug 14 '25	Sale	3.02	11,161	33,695	224,094	Aug 18 04:35 PM
Militello John	See Remarks	Aug 14 '25	Sale	3.02	7,043	21,263	56,984	Aug 18 04:35 PM
Wilson Martin	General Counsel	Aug 14 '25	Sale	3.02	12,109	36,557	137,054	Aug 18 04:35 PM
Wilson Martin	Officer	Aug 18 '25	Proposed Sale	3.07	1,004	3,077		Aug 18 03:24 PM
Militello John	Officer	Aug 18 '25	Proposed Sale	3.07	699	2,143		Aug 18 03:10 PM
Schwartz Jonathan David	Officer	Aug 18 '25	Proposed Sale	3.07	1,680	5,150		Aug 18 03:10 PM
Militello John	Officer	Aug 14 '25	Proposed Sale	3.02	7,043	21,261		Aug 14 05:55 PM
Wilson Martin	Officer	Aug 14 '25	Proposed Sale	3.02	12,109	36,553		Aug 14 05:47 PM
Schwartz Jonathan David	Officer	Aug 14 '25	Proposed Sale	3.02	11,161	33,692		Aug 14 05:44 PM
Ondrey Aaron	Chief Financial Officer	Jul 03 '25	Sale	2.88	1,477	4,257	128,173	Jul 08 04:05 PM
Ondrey Aaron	Officer	Jul 03 '25	Proposed Sale	2.88	1,477	4,256		Jul 03 03:17 PM
Militello John	See Remarks	May 20 '25	Sale	6.45	357	2,301	64,027	May 22 04:05 PM
Schwartz Jonathan David	See Remarks	May 20 '25	Sale	6.45	801	5,163	235,255	May 22 04:05 PM
Patel Kinnari	See Remarks	May 20 '25	Sale	6.45	767	4,944	441,927	May 22 04:05 PM
Shah Gaurav	CEO	May 20 '25	Sale	6.45	2,253	14,523	786,806	May 22 04:05 PM
Wilson Martin	General Counsel	May 20 '25	Sale	6.45	587	3,784	149,163	May 22 04:05 PM
Militello John	See Remarks	May 16 '25	Sale	6.53	655	4,276	64,384	May 20 04:05 PM
Patel Kinnari	See Remarks	May 16 '25	Sale	6.53	1,409	9,198	442,694	May 20 04:05 PM
Schwartz Jonathan David	See Remarks	May 16 '25	Sale	6.53	1,582	10,327	236,056	May 20 04:05 PM
Shah Gaurav	CEO	May 16 '25	Sale	6.53	3,621	23,638	789,059	May 20 04:05 PM
Wilson Martin	General Counsel	May 16 '25	Sale	6.53	946	6,175	149,750	May 20 04:05 PM
Wilson Martin	Officer	May 20 '25	Proposed Sale	6.45	587	3,784		May 20 03:29 PM
Militello John	Officer	May 20 '25	Proposed Sale	6.45	357	2,301		May 20 03:21 PM
Schwartz Jonathan David	Officer	May 20 '25	Proposed Sale	6.45	801	5,163		May 20 03:17 PM
Shah Gaurav	Officer	May 20 '25	Proposed Sale	6.45	2,253	14,523		May 20 03:15 PM
Patel Kinnari	Officer	May 20 '25	Proposed Sale	6.45	767	4,944		May 20 03:13 PM
Schwartz Jonathan David	Officer	May 16 '25	Proposed Sale	6.53	1,582	10,327		May 16 04:13 PM
Shah Gaurav	Officer	May 16 '25	Proposed Sale	6.53	3,621	23,636		May 16 04:09 PM
Wilson Martin	Officer	May 16 '25	Proposed Sale	6.53	946	6,175		May 16 04:07 PM
Militello John	Officer	May 16 '25	Proposed Sale	6.53	655	4,276		May 16 03:32 PM
Patel Kinnari	Officer	May 16 '25	Proposed Sale	6.53	1,409	9,197		May 16 03:18 PM
Militello John	See Remarks	Apr 22 '25	Sale	7.16	718	5,139	65,039	Apr 24 04:06 PM
Militello John	Officer	Apr 22 '25	Proposed Sale	7.16	718	5,140		Apr 22 03:17 PM
Shah Gaurav	CEO	Apr 10 '25	Buy	5.08	20,000	101,600	792,680	Apr 14 06:57 PM
Patel Kinnari	See Remarks	Apr 09 '25	Buy	4.70	21,099	99,165	26,774	Apr 10 04:07 PM
White Mark Andrew	Former Officer	Apr 09 '25	Proposed Sale	4.67	3,382	15,777		Apr 09 03:26 PM
Ondrey Aaron	Chief Financial Officer	Apr 04 '25	Sale	5.29	7,489	39,647	129,650	Apr 08 04:06 PM
Ondrey Aaron	Officer	Apr 04 '25	Proposed Sale	5.29	7,489	39,647		Apr 04 03:25 PM
Schwartz Jonathan David	See Remarks	Feb 25 '25	Sale	10.58	6,532	69,109	237,638	Feb 27 04:01 PM
Schwartz Jonathan David	See Remarks	Nov 21 '24	Sale	13.05	3,097	40,416	163,852	Feb 27 04:01 PM
Patel Kinnari	See Remarks	Feb 21 '25	Sale	10.58	6,078	64,305	444,103	Feb 25 04:01 PM
Wilson Martin	General Counsel	Feb 21 '25	Sale	10.58	3,222	34,089	150,696	Feb 25 04:01 PM
Militello John	See Remarks	Feb 21 '25	Sale	10.58	2,737	28,957	65,757	Feb 25 04:01 PM
Shah Gaurav	CEO	Feb 21 '25	Sale	10.58	16,303	172,486	772,680	Feb 25 04:01 PM
Schwartz Jonathan David	Officer	Feb 25 '25	Proposed Sale	10.58	6,532	69,117		Feb 25 12:56 PM
Patel Kinnari	Officer	Feb 21 '25	Proposed Sale	10.58	6,078	64,313		Feb 21 04:29 PM
White Mark Andrew	Former Officer	Feb 21 '25	Proposed Sale	10.58	1,222	12,930		Feb 21 04:15 PM
Wilson Martin	Officer	Feb 21 '25	Proposed Sale	10.58	3,222	34,093		Feb 21 04:11 PM
Shah Gaurav	Officer	Feb 21 '25	Proposed Sale	10.58	16,303	172,507		Feb 21 04:11 PM
Militello John	Officer	Feb 21 '25	Proposed Sale	10.58	2,737	28,961		Feb 21 04:09 PM
White Mark Andrew	Former Officer	Jan 31 '25	Proposed Sale	10.96	2,824	30,943		Jan 31 03:15 PM
Militello John	See Remarks	Jan 23 '25	Sale	10.38	896	9,300	48,414	Jan 27 04:16 PM
Militello John	Officer	Jan 23 '25	Proposed Sale	10.38	896	9,301		Jan 23 03:33 PM
Militello John	See Remarks	Nov 21 '24	Sale	13.05	1,224	15,978	49,310	Nov 25 04:05 PM
Patel Kinnari	See Remarks	Nov 21 '24	Sale	13.05	4,588	59,892	392,395	Nov 25 04:05 PM
Shah Gaurav	CEO	Nov 21 '24	Sale	13.05	11,091	144,782	707,328	Nov 25 04:05 PM
Wilson Martin	General Counsel	Nov 21 '24	Sale	13.05	1,175	15,338	63,560	Nov 25 04:05 PM
Patel Kinnari	Officer	Nov 21 '24	Proposed Sale	13.05	4,588	59,892		Nov 21 04:26 PM
Militello John	Officer	Nov 21 '24	Proposed Sale	13.05	1,224	15,978		Nov 21 04:06 PM
Wilson Martin	Officer	Nov 21 '24	Proposed Sale	13.05	1,175	15,338		Nov 21 03:58 PM
Shah Gaurav	Officer	Nov 21 '24	Proposed Sale	13.05	11,091	144,782		Nov 21 03:27 PM
White Mark Andrew	See Remarks	Oct 31 '24	Sale	16.62	3,080	51,205	69,140	Nov 04 04:06 PM
Militello John	See Remarks	Oct 31 '24	Sale	16.62	917	15,245	50,534	Nov 04 04:05 PM
Militello John	Officer	Oct 31 '24	Proposed Sale	16.62	917	15,245		Oct 31 03:34 PM
White Mark Andrew	Officer	Oct 31 '24	Proposed Sale	16.62	3,080	51,205		Oct 31 03:24 PM

PTCT

PTC Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Upgrade your FINVIZ experience